The Big Picture
Across three Huberman Lab conversations, researchers present psychedelics as a promising but scientifically complex group of drugs. Matthew Johnson divides the field into classes. The classic psychedelics (LSD, psilocybin, DMT and mescaline) act as agonists or partial agonists at the serotonin 2A receptor. NMDA antagonists such as ketamine, and the kappa opioid agonist salvinorin A, can also be called psychedelic. MDMA sits in a class of its own as an entactogen [1]. Robin Carhart-Harris covers the clinical science, including:
- how psilocybin sessions are run
- increased brain connectivity linked to recovery from depression
- emerging trials in anorexia and fibromyalgia
- the regulatory road ahead for MDMA and psilocybin [2]
Robert Malenka, a neuroscientist who credits his own youthful experimentation with partly sparking his interest in the brain, describes himself as "excited but not evangelical." He emphasizes how much remains unexplained about how these molecules produce their effects [3].
The shared message is that these compounds can reshape mood, perception and sense of self in ways that may help treat depression, addiction and trauma [1][2]. The experts also stress that the categories, the mechanisms and even the definition of "psychedelic" are still being worked out [1][2][3].
Where the Experts Agree
- Classic psychedelics work through the serotonin 2A receptor. Johnson identifies LSD, psilocybin, DMT and mescaline as serotonin 2A agonists or partial agonists [1]. In conversation with Malenka, Huberman makes the same point about psilocybin and LSD, and Malenka accepts that framing [3].
- MDMA is different. Johnson calls MDMA an entactogen that works mainly by releasing serotonin rather than mimicking it at the receptor [1]. Malenka likewise separates classical hallucinogens from entactogens and empathogens like MDMA [3]. Carhart-Harris discusses MDMA as its own topic, including psilocybin-MDMA combinations [2].
- Chemistry and biology don't map neatly onto experience. Johnson notes that mescaline structurally resembles dopamine more than serotonin, yet it acts on the same receptor as psilocybin [1]. Malenka points out there are 16 serotonin receptor types, which he calls a "daunting complexity" [3]. Carhart-Harris highlights the tension between defining these drugs by their pharmacology or by subjective experience [2].
- There is real therapeutic potential. Johnson notes that esketamine (Spravato), a nasal form of ketamine, is FDA approved for treatment-resistant depression [1]. Carhart-Harris links psilocybin's increase in global brain connectivity to recovery from depression [2]. Malenka sees the receptor complexity as creating therapeutic opportunities [3].
- Rigorous research matters. Johnson's group ran the first blinded controlled human research on salvinorin A [1]. Carhart-Harris describes a self-blinded microdosing study [2]. Malenka credits MAPS and founder Rick Doblin for a 30-year effort to make rigorous, ethical MDMA research possible [3].
Where They Differ
- How to explain what psychedelics do. When Huberman asks whether psychedelics alter the brain's analysis of space and time, Johnson pushes back. He notes that alcohol and benzodiazepines disrupt that too. He prefers to describe the brain as a "prediction machine" and psychedelics as loosely dissolving the models it builds, from how a ball falls to who we think we are [1]. Carhart-Harris emphasizes measurable changes in brain wiring instead. These include increased global connectivity and lasting changes after a single 25-milligram first-time dose [2]. The two framings are not contradictory, but one is cognitive and the other network-based.
- How broad the category is. Johnson takes an expansive view and includes ketamine, PCP, dextromethorphan and salvinorin A as psychedelics of other kinds [1]. Malenka draws tighter lines between hallucinogens and entactogens. He flags ibogaine, ayahuasca and peyote as "complex cases" rather than folding them neatly into one group [3].
- Degree of enthusiasm. Carhart-Harris presents an ambitious clinical and policy agenda that extends to anorexia, fibromyalgia and the legal path for MDMA and psilocybin [2]. Malenka is deliberately cautious [3]. His fascination is mechanistic: a drug with specific molecular targets has a relatively specific effect on social behavior and "does not make you want more donuts" [3].
- The role of expectation. Carhart-Harris reports that a self-blinded microdosing study found placebo matched microdosing [2]. This suggests expectation may drive the reported benefits of small doses. Yet he also reports that expectancy did not predict psilocybin's effects in emerging trials [2]. The tension in this case is between dose regimes rather than between speakers.
Practical Takeaways
- Don't treat "psychedelics" as one thing. Serotonin 2A agonists, NMDA antagonists like ketamine, kappa opioid agonists and entactogens like MDMA work through different mechanisms [1][3].
- Be skeptical of microdosing claims. In a self-blinded study Carhart-Harris discusses, placebo matched microdosing [2].
- Know that one ketamine-based option is already approved. Spravato (esketamine) is FDA approved for treatment-resistant depression [1].
- Expect clinical psilocybin to look structured, not recreational. Carhart-Harris describes two therapists, eye masks, carefully built music, and the guiding mantra "trust, let go, be open" [2].
- Look beyond the dosing session itself. Carhart-Harris raises relapse and integration as key issues for lasting benefit [2].
- Don't assume a compound's effects from its chemical structure. Mescaline is the cautionary example [1], and the 16 serotonin receptor types add further unpredictability [3].
- Remember that altered perception isn't unique to psychedelics. Johnson notes alcohol and benzodiazepines also disrupt the brain's sense of space and time [1].
- Follow the regulatory process. The legal and regulatory road for MDMA and psilocybin is still ahead [2], built on decades of research advocacy [3].
